Judge trims EmblemHealth's US antitrust claims against Alexion over Soliris
By Clayton Vickers ( December 19, 2025, 23:13 GMT | Insight) -- EmblemHealth’s US antitrust claims against Alexion Pharmaceuticals alleging unlawful delay of competition for its drug Soliris were trimmed Friday by a Massachusetts federal judge. US District Judge Brian Murphy dismissed Emblem’s claims based on allegations that Alexion obtained its patents through fraud against the US Patent and Trademark Office, but allowed its claims alleging that Alexion engaged in sham patent litigation against its competitors to proceed.EmblemHealth’s US antitrust claims against Alexion Pharmaceuticals alleging unlawful delay of competition for its drug Soliris were trimmed Friday by a Massachusetts federal judge. US District Judge Brian Murphy dismissed Emblem’s claims based on allegations that Alexion obtained its patents through fraud against the US Patent and Trademark Office, but he allowed to proceed its claims alleging that Alexion engaged in sham patent litigation against its competitors....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.